Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progress and challenges in RET-targeted cancer therapy.
Hu X, Khatri U, Shen T, Wu J. Hu X, et al. Among authors: shen t. Front Med. 2023 Apr;17(2):207-219. doi: 10.1007/s11684-023-0985-y. Epub 2023 May 3. Front Med. 2023. PMID: 37131086 Review.
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, Makanji RJ, Martinez GV, Shen T, Zhao L, Fung KM, Haura EB, Coppola D, Wu J. Huang Q, et al. Among authors: shen t. Mol Cancer Ther. 2016 Oct;15(10):2521-2529. doi: 10.1158/1535-7163.MCT-16-0258. Epub 2016 Aug 5. Mol Cancer Ther. 2016. PMID: 27496134 Free PMC article.
Drug resistance profiles of mutations in the RET kinase domain.
Liu X, Shen T, Mooers BHM, Hilberg F, Wu J. Liu X, et al. Among authors: shen t. Br J Pharmacol. 2018 Sep;175(17):3504-3515. doi: 10.1111/bph.14395. Epub 2018 Jul 19. Br J Pharmacol. 2018. PMID: 29908090 Free PMC article.
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Subbiah V, et al. Among authors: shen t. Ann Oncol. 2021 Jun;32(6):817-819. doi: 10.1016/j.annonc.2021.02.010. Epub 2021 Feb 20. Ann Oncol. 2021. PMID: 33617938 Free PMC article. No abstract available.
RET kinase alterations in targeted cancer therapy.
Liu X, Hu X, Shen T, Li Q, Mooers BHM, Wu J. Liu X, et al. Among authors: shen t. Cancer Drug Resist. 2020 May 11;3(3):472-481. doi: 10.20517/cdr.2020.15. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582449 Free PMC article. Review.
3,693 results